Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Peripheral T Cell Lymphoma, T-cell Acute Lymphoblastic Leukemia, T Lymphoblastic Leukemia/Lymphoma
Conditions
Keywords
chimeric antigen receptor T cell, T lymphoblastic lymphoma/leukemia, T cell non-Hodgkin lymphoma, CD7
Brief summary
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
Detailed description
This study is single-armed，open lable，dose escalation clinical trial.The main purpose is to evaluate the safety and efficacy of anti-CD7 CAR-T cells in relapsed/refractory patients with CD7 positive T cell malignancies,including T lymphoblastic lymphoma/leukemia ,T-cell non-Hodgkin lymphoma(peripheral T cell lymphoma,NOS,angioimmunoblastic T cell lymphoma and anaplastic large cell lymphoma).There will be three CAR T cell dose groups:0.25\*10\^6 cells per kilogram of body weight;0.5\*10\^6 cells per kilogram of body weight，1 \*10\^6 ells per kilogram of body weight.
Interventions
DRUGanti-CD7 CAR-T cells
Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
Sponsors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Fourteen to 70 Years Old, Male and female; 2. Expected survival \> 12 weeks; ECOG score 0-2; 3. Confirmed diagnosis of acute T cell leukemia and screened for CD7 positive,including following conditions:a. Patients who do not get a CR with ≥2 prior induction therapy b. Those who achieves CR, but have a early relapse(\<12months),or a late relapse (\>=12months) failing to acheive a CR after re-induction chemotherapy c. For any Patiens failed ASCT/allo-SCT 4. Relapsed and refractory patients with diagnosis of CD7 positive T cell lymphoma have had≥2 prior lines of therapy,who do not acheive at least a PR, or have a relapse including:a. Peripheral T cell lymphoma NOS, or b.Angioimmunoblastic T cell lymphoma,or c. Anaplastic large cell lymphoma c.Disease can be assessed(BM or CT scan) 5. Confirmed T lymphoblastic lymphoma：a. Patients who do not get a PR with ≥2 induction chemotherapy or a CR with ≥ 4 induction chemotherapy b. Relapsed patients failing to achieve a CR after 1 line salvage chemotherapy c. For any Patients failed ASCT/allo-SCT .Disease can be assessed(BM or CT scan) 6. The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators; 7. Liver, kidney and cardiopulmonary functions meet the following requirements: a. Ccr≥60mL/min(Cockcroft Gault) b. Left ventricular ejection fraction \>50%; c.Baseline oxygen saturation\>92%; d. Total bilirubin ≤ 1.5×ULN; e. ALT and AST≤ 3×ULN; 8. Able to understand and sign the Informed Consent
Exclusion criteria
1. Malignant tumors other than T cell malignancies within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection; 2. Uncontrolled infection including bacteral or virus or fugal disease;patients with positive HBsAg or HBcAb and positive peripheral blood HBV DNA titer detection ;HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; syphilis positive; 3. Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening),myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia,liver, kidney, or metabolic disease; 4. Any uncontrolled disease may affect entry 5. Current or history of CNS involvement by malignancy.Known history or presence of clinically relevant central nervous system (CNS) pathology.Patients with a known history or prior diagnosis other immunologic or inflammatory disease affecting the CNS (such as epilepsy) 6. Patients who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion; 7. Subjects treated with anti-PD1 or anti-PDL1 therapies within 3months before enrollment 8. Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pr egnancy within 1 year after cell transfusion; 9. Active or uncontrollable infection requiring systemic therapy Received CAR-T treatment or other gene therapies before enrollment; 10. Kown be allergic to anti-TRBC1 CAR-T cells or drugs(Fludarabine or Cyclophophamide) 11. The investigators consider other conditions unsuitable for enrollment. 12. Patients who may not be able to sign the Informed Consent due to disease,or who do not understand or unwillingness or inability to comply with research requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | 28 days post infusion | The occurence of study related adverse effects defined by NCI CTCAE5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CAR-T cell expansion | 2 years post infusion | Using flow cytometry to reveal cell surface expression of the CAR protein on T cells;and using quantitative polymerase chain reaction to detect DNA copies of the transgene irrespective of gene expression(per ug DNA) to evaluate anti-CD7 CAR-T cell expansion after infusion |
| CAR-T cell persistence | 2 years post infusion | Using flow cytometry to reveal cell surface expression of the CAR protein on T cells;and using quantitative polymerase chain reaction to detect DNA copies of the transgene irrespective of gene expression(per ug DNA) to evaluate anti-CD7 CAR-T cell persistence after infusion |
| Number of CD7+ lymphocytes of peripheral blood | 2 years post infusion | To evaluate CD7 positive cells of peripheral blood after infusion |
| Duration of remission (DOR) after administration | 2 years post infusion | Duration of remission (DOR) after administration |
| Overall survival(OS) after administration | 2 years post infusion | Overall Survival (OS)after administration |
| Progression Free Survival (PFS) after administration | 2 years post infusion | Progression Free Survival (PFS) after administration |
| Total response rate (ORR) after administration | 3 months post infusion | CR+CRi for T-ALL ;CR+PR for T cell lyphoma and T lymphoblastic lymphoma |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of CAR-T cells | 2 years post infusion | Using flow cytometry to detect whether anti-car antibodies are contained in serum of patients receiving CAR-T cells infusion,and to evaluate the number of participants with antibodies |
Countries
China
Outcome results
None listed